Boehringer Ingelheim Collaborated with Riboure Pharmaceuticals to Develop RNAi Based Therapies for the Treatment of Liver Diseases
Shots:
- Boehringer Ingelheim partnered with Ribo to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH)
- Under the terms of the agreement, Ribo will receive an up front payment, success-based milestones payments for clinical, regulatory & commercial success plus tiered royalties. The overall deal value will add up to an aggregate of $2B
- The partnership will combine Boehringer's dedication to developing treatments for cardiovascular, renal & metabolic diseases (CRM) with Ribo's capabilities in the research & clinical development of small interfering RNA (siRNA) therapies. Moreover the collaboration with leverage Ribo’s RIBO-GalSTAR platform to develop RNAi therapies
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
